Total Body Photography and Sequential Digital Dermoscopy Imaging for Melanoma Surveillance in Patients Starting Natalizumab for Multiple Sclerosis
نویسندگان
چکیده
Introduction: Natalizumab is an integrin receptor antagonist that has been approved by the Food and Drug Administration to treat multiple sclerosis Crohn’s disease. The drug linked increased risk of melanoma. This brief report highlights innovative clinical approach for monitoring skin patients prescribed natalizumab.
منابع مشابه
Natalizumab for relapsing multiple sclerosis.
To the Editor: As Ropper pointed out in his editorial (March 2 issue),1 the three articles on the use of natalizumab in that issue of the Journal are pivotal, but his conclusion that natalizumab is “a potent treatment for multiple sclerosis” may be too sanguine. The similar entry criteria, treatment, and methods of analysis permit clinically useful conclusions to be drawn from the placebocontro...
متن کاملNatalizumab treatment for multiple sclerosis.
Correspondence: Maria Lucia Brito Ferreira; Rua Doutor José Maria, 841; 52040-000 Recife PE, Brasil; E-mail: [email protected] Conflict of interest: There is no conflict of interest to declare. Received 23 September 2014 Accepted 01 October 2014 The last five years had as benchmark the development of new drugs for treatment of multiple sclerosis. Its treatment has become complex because othe...
متن کاملNatalizumab in pediatric multiple sclerosis patients.
Pediatric multiple sclerosis (MS) comprises 2-5% of all cases of MS. Although first-line disease-modifying therapy (DMT) including interferons and glatiramer acetate appear to be well tolerated in this population, recent work has suggested that a growing number of children suffer from disease which is resistant to treatment with these therapies. Natalizumab is a therapy which, although associat...
متن کاملGlioblastoma in natalizumab‐treated multiple sclerosis patients
We present two natalizumab-treated multiple sclerosis patients who developed glioblastoma multiforme (GBM) with variable outcomes. One patient had an isocitrate dehydrogenase (IDH)-wildtype GBM with aggressive behavior, who declined treatment and died 13 weeks after symptoms onset. The other patient underwent resection of an IDH-mutant secondary GBM that arose from a previously diagnosed grade ...
متن کاملUse of natalizumab in multiple sclerosis patients.
Natalizumab is a monoclonal antibody indicated in Canada as monotherapy for the treatment of multiple sclerosis (MS) patients with relapsing-remitting disease. The phase III clinical trial of natalizumab monotherapy demonstrated substantial improvements in clinical and magnetic resonance imaging (MRI) parameters in patients with relapsing-remitting MS, with statistically significant reductions ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Maine Medical Center
سال: 2021
ISSN: ['2641-2225']
DOI: https://doi.org/10.46804/2641-2225.1083